We seek highly motivated and experienced professionals with backgrounds in oncology, immunology, and drug development to join our team. Please send your resume and cover letter in confidence to

Open Opportunity

Scientist Position at BriaCell Therapeutics Corp.
Berkeley, CA

Full-time position at BriaCell Therapeutics Corp., a clinical-stage, public immuno-oncology company located in Berkeley, CA. At BriaCell, we are strongly motivated to advance our pipeline of products to provide hope for cancer patients with little options. The successful candidate will work in a vibrant startup incubator environment with rapidly changing priorities and is expected to supervise technical personnel, come up with creative engineering solutions for cell-based therapeutics, is well-versed in immunotherapy, and preferentially has experience with GLP/GMP manufacturing of cellular products,. The candidate is expected to manage multiple projects including coordination with contract research organizations for outsourced aspects and will conduct laboratory bench work to support in-house projects.

Interested in working with us? Please send us your CV/résumé and a compelling cover letter outlining why you think you are a good fit (to:

Minimal Requirements

• Ph.D. in cell biology, immunology, molecular biology or similar
• At least 5 years of combined industry or post-doctoral academic experience
• Solid understanding of Good Documentation Practices (GDP) and familiarity of Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) principles
• In-depth experience with engineering of cell lines (preferably cancer cells) and derivation of clonal cell lines
• Strong knowledge and hands-on experience with techniques related to immune biology, molecular biology, and biochemistry including methods such as multicolor flow cytometry, ELISpot, protein analysis by ELISA or Luminex, culturing of immune cells including expansion of T cells and derivation of immune cell subsets such as dendritic cells from PBMCs, RNA/DNA isolation and plasmid vector generation, and Western blotting or similar. Experience with CRISPR/Cas9, TALEN, or zinc finger nuclease-based approaches, or similar is a plus.
• Performance of screening assays for small molecule kinase inhibitors and other general bioassays (cellular proliferation, viability, etc.) or ability to perform similar assays.
• Competent in assay development, data interpretation, and troubleshooting.
• Up to date with literature on immunotherapy
• Prior managing experience is a plus
• Self-motivated/ability to work under minimal supervision
• Outstanding communication skills both in meetings and by written communication
• Analytical and creative mindset, able to stay calm in fast-paced environment with rapidly changing priorities
• Excellent work ethics

About BriaCell

BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. Immunotherapy has come to the forefront in the fight against cancer because it uses the body’s own immune system in recognizing and selectively destroying cancer cells while leaving normal cells intact. In addition, immunotherapy is also considered to be a more potent approach than chemotherapy, and has the potential to prevent cancer recurrence.

Bria-IMT™ (SV-BR-1-GM), the Company’s lead product candidate, is derived from a specific breast cancer cell line. It is genetically engineered to release granulocyte-macrophage colony-stimulating factor (GM-CSF), a substance that activates the immune system. BriaCell believes that Bria-IMT™ helps the body to recognize and kill tumor cells by activating both T cells that directly attack tumor cells, and B cells that produce anti-tumor antibodies.

The results of two previous proof-of-concept clinical trials (one with the precursor cell line not genetically engineered to produce GM-CSF and one with Bria-IMT™) produced encouraging results in patients with advanced breast cancer. Most notably, one patient with breast cancer that had spread to other sites (metastatic cancer) responded to Bria-IMT™ with a substantial reduction in tumor size and volume in these sites, including sites in the breast, the lung, soft tissues, and even the brain. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT™ in patients with advanced breast cancer. In this trial, to date, Bria-IMT™ treatment has been safe with instances of tumor reduction observed. This trial is listed in as NCT03066947. The trial is being conducted along with the co-development of BriaDX™, the Company’s companion diagnostic test, to be able to predict the patients who will likely benefit the most from Bria-IMT™ treatments. Additionally, the FDA recently approved a rollover combination study of Bria-IMT™ with pembrolizumab [Keytruda®; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy®; manufactured by Bristol-Myers Squibb Company]. This study permits continuation of the Bria-IMT™ treatment for patients in the ongoing Phase I/IIa trials who stop responding to the treatment. The rollover trial is listed in as NCT03328026.

Based on our observation of superior tumor shrinking responses in the patients who shared certain HLA types with Bria-IMT™, BriaCell is developing Bria-OTS™, an off-the-shelf personalized Immunotherapy, for advanced breast cancer. Bria-OTS™ includes a set of cell lines, each being similar to Bria-IMT™, which are being engineered to express various pre-manufactured HLA types. With only 15 different HLA types, Bria-OTS™ cell line combinations are expected to cover over 90% of the US population. BriaCell expects to use BriaDX™ to determine the HLA types of patients, and subsequently select one or two Bria-OTS™ cell lines with matching alleles to be administered to the patient. This should produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics currently used for other personalized immunotherapies. In essence, Bria-OTS™ should provide a personalized treatment without the need for personalized manufacturing.

BriaCell’s small molecule program includes the development of novel, selective protein kinase C delta (PKCδ) inhibitors which have shown potent activity in a number of pre-clinical models of several different cancer indications as well as fibrotic diseases.